Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAVENCLAD vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
FDA: Treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease.
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life of cladribine is approximately 5.7 days (range 4-10 days) following oral administration. This long half-life supports once-daily high-dose short-course dosing and is due to slow release from lymphocytes. Clinical context: Allows sustained intracellular levels of active triphosphate in lymphocytes.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate metabolite. It is also phosphorylated by other nucleoside kinases. The elimination half-life is approximately 1 day. Renal excretion of unchanged drug accounts for about 18% of the dose.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Approximately 100% of cladribine dose is eliminated via renal excretion of unchanged drug and metabolites, with <5% recovered in feces. Renal clearance is about 2/3 of total clearance. Biliary elimination is negligible.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
20% bound to plasma proteins, primarily albumin. No significant binding to alpha1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
Apparent volume of distribution is approximately 4.3 L/kg (range 1-9 L/kg). This large Vd indicates extensive extravascular distribution, including penetration into cells and tissues, particularly lymphocytes. Clinical meaning: High tissue distribution correlates with intracellular loading in target immune cells.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral bioavailability of cladribine from MAVENCLAD is approximately 40% (range 30-50%). It is converted to active triphosphate intracellularly, so prodrug absorption is similar. Food reduces absorption by ~20% but does not affect clinical effect.
IV: 100% (only IV route); oral: not approved
Contraindicated in patients with estimated GFR <30 m L/min/1.73 m2 due to potential accumulation and increased risk of adverse reactions. No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2).
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Not approved for use in pediatric patients less than 18 years of age. Safety and efficacy have not been established.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment recommended based on age alone. However, renal function should be assessed and dosing should be based on e GFR as in younger adults. Experience in patients over 60 years of age is limited.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
WARNING: MALIGNANCIES. Cladribine can increase the risk of malignancies (including cases of cancer-related deaths). Because of this risk, MAVENCLAD should be used in patients who have had an inadequate response to, or are unable to tolerate, other drugs indicated for the treatment of MS.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Risk of malignancies: including treatment-emergent malignancies (e.g., cancers of the lung, gastrointestinal tract, skin, breast, and others).,Hematologic toxicity: severe bone marrow suppression (thrombocytopenia, anemia, neutropenia); monitor CBC counts before and during treatment.,Infections: increased risk of serious infections, including opportunistic infections (e.g., tuberculosis, herpes zoster, progressive multifocal leukoencephalopathy); screen for latent infections before initiation.,Hepatic injury: cases of drug-induced liver injury; monitor liver enzymes.,Fetal risk: can cause fetal harm; advise females of reproductive potential to use effective contraception during and for 6 months after the last dose.,Vaccinations: avoid live vaccines during and after treatment.,Impaired renal function: use with caution; cladribine pharmacokinetics may be altered.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Current malignancy.,Patients with HIV infection.,Active chronic infections (e.g., tuberculosis, hepatitis).,Hypersensitivity to cladribine or any component of the formulation.,Women who are pregnant or breastfeeding.,Concomitant use with other immunosuppressive or myelosuppressive therapies (except corticosteroids for acute exacerbations).
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No significant food interactions reported. Avoid grapefruit and grapefruit juice as they may alter drug metabolism.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of fetal harm, including teratogenicity and embryolethality. In humans, no adequate controlled studies exist; therefore, use in all trimesters is contraindicated. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
It is unknown whether cladribine is excreted in human breast milk. However, due to the potential for serious adverse reactions in nursing infants and the drug's long half-life, breastfeeding is not recommended during treatment and for at least 10 days after the last dose. M/P ratio is not available.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
MAVENCLAD is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as the drug is not to be administered to pregnant women.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Mavenclad (cladribine) is an oral purine antimetabolite approved for relapsing multiple sclerosis. It is given as two short courses per year for two years. Monitor for lymphopenia, infections, and malignancies. Contraindicated in patients with active infections or current malignancy. Do not use in patients with HIV or hepatitis B/C. Live vaccines contraindicated during and after treatment. Pregnancy category D; effective contraception required. Monitor liver enzymes and bilirubin. Consider PCP and VZV prophylaxis if lymphopenia severe. MRI monitoring for PML is recommended.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Mavenclad is taken in two treatment courses per year, each consisting of 4 or 5 days of tablets, for 2 years.,You need regular blood tests to monitor your white blood cell count, liver function, and for infections.,Avoid live vaccines during treatment and for at least 1 year after the last dose.,Use effective contraception during treatment and for at least 6 months after the last dose.,Report any signs of infection (fever, chills, cough), unusual bleeding, or easy bruising immediately.,Do not take Mavenclad if you have an active infection, cancer, or HIV/hepatitis B or C.,Avoid grapefruit products during treatment.,Store tablets at room temperature away from moisture.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAVENCLAD vs CLOFARABINE, answered by our medical review team.
MAVENCLAD is a Antineoplastic Agent that works by Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAVENCLAD and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAVENCLAD is: 3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAVENCLAD and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAVENCLAD is classified as Category C. MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of . CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.